−0.125AUD
−14.05 MAUD
16.94 MAUD
132.71 M
About GENETIC SIGNATURES LIMITED
Sector
CEO
John R. Melki
Website
Headquarters
Newtown
Founded
2001
ISIN
AU000000GSS4
FIGI
BBG007J39F86
Genetic Signatures Ltd. is a research company, which engages in the identification and commercialization of individual genetic signatures for the diagnosis of infectious diseases. It is also involved in the sale of associated products into the diagnostic and research marketplaces. Its products include the treatment for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. It operates in the following geographical segments: Asia Pacific, Europe, Middle East, and Africa (EMEA), and Americas. The company was founded by Robert J. Birrell, Christopher M. Abbott, and Geoffrey Grigg on February 15, 2001 and is headquartered in Newtown, Australia.
$GSS Quarterly results support the sp. Or is it the other way?ATH close tonight. Seemed to be itchy to break $2 before the close. Looks like Q4 revenue should be a minimum of $5M which is over 200% increase on any other quarter. A growth stock if ever I saw one. See if it follows through tomorrow and then onto who knows where.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of GSS is 0.690 AUD — it has decreased by 1.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange GENETIC SIGNATURES LIMITED stocks are traded under the ticker GSS.
GENETIC SIGNATURES LIMITED is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
GSS stock is 6.06% volatile and has beta coefficient of 0.58. Check out the list of the most volatile stocks — is GENETIC SIGNATURES LIMITED there?
One year price forecast for GENETIC SIGNATURES LIMITED has a max estimate of 0.750 AUD and a min estimate of 0.750 AUD.
GSS earnings for the last quarter are −0.05 AUD per share, whereas the estimation was −0.05 AUD resulting in a 5.36% surprise. The estimated earnings for the next quarter are −0.03 AUD per share. See more details about GENETIC SIGNATURES LIMITED earnings.
GENETIC SIGNATURES LIMITED revenue for the last quarter amounts to 8.70 M AUD despite the estimated figure of 6.50 M AUD. In the next quarter revenue is expected to reach 3.60 M AUD.
Yes, you can track GENETIC SIGNATURES LIMITED financials in yearly and quarterly reports right on TradingView.
GSS stock has risen by 1.47% compared to the previous week, the month change is a 11.29% rise, over the last year GENETIC SIGNATURES LIMITED has showed a 16.89% decrease.
GSS net income for the last quarter is −10.47 M AUD, while the quarter before that showed −7.57 M AUD of net income which accounts for −38.26% change. Track more GENETIC SIGNATURES LIMITED financial stats to get the full picture.
Today GENETIC SIGNATURES LIMITED has the market capitalization of 130.54 M, it has increased by 3.70% over the last week.
No, GSS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GSS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENETIC SIGNATURES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENETIC SIGNATURES LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENETIC SIGNATURES LIMITED stock shows the neutral signal. See more of GENETIC SIGNATURES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GENETIC SIGNATURES LIMITED future price: according to them, GSS price has a max estimate of 0.75 AUD and a min estimate of 0.75 AUD. Read a more detailed GENETIC SIGNATURES LIMITED forecast: see what analysts think of GENETIC SIGNATURES LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENETIC SIGNATURES LIMITED EBITDA is −22.78 M AUD, and current EBITDA margin is −102.51%. See more stats in GENETIC SIGNATURES LIMITED financial statements.